caa a22 4500 477061990 CHVBK 20180405111403.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/BF00133072 doi (NATIONALLICENCE)springer-10.1007/BF00133072 Current clinical experience with staphylokinase in arterial thrombosis [Elektronische Daten] [Steven Vanderschueren, Désiré Collen, Frans Van de Werf] Conclusions: Sak, a profibrinolytic agent produced by S. aureus that is now readily available by recombinant DNA technology, induces efficient and rapid recanalization in patients with occlusive arterial thrombosis. Its fibrin specificity at clinically effective doses by far exceeds that of any commercially available plasminogen activator. Likewise, the speed and rate of clot lysis compare favorably with established agents, but definition of the relative benefits, especially in terms of reduction of mortality and morbidity, awaits larger comparative trials. The optimal dose and rate of infusion in patients with coronary and peripheral arterial thrombosis, as well as the value of Sak in other thromboembolic disorders (comprising deep venous thrombosis, pulmonary embolism, and ischemic stroke), remain to be established. Notwithstanding its short circulatory half-life, bolus thrombolysis with Sak appears to be feasible. The antigenicity of wild-type Sak argues against repeated administration, but limited experience with selected recombinant mutants indicates that the immunoreactivity and antigenicity of this bacterial protein can at least be attenuated while preserving fibrinolytic activity and fibrin specificity. Kluwer Academic Publishers, 1996 thrombolysis nationallicence acute myocardial infarction nationallicence staphylokinase nationallicence thrombosis nationallicence Vanderschueren Steven Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium aut Collen Désiré Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium aut Van de Werf Frans Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 3/4(1996-12-01), 297-300 0929-5305 3:4<297 1996 3 11239 https://doi.org/10.1007/BF00133072 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00133072 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Vanderschueren Steven Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium aut NATIONALLICENCE 700 1- Collen Désiré Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium aut NATIONALLICENCE 700 1- Van de Werf Frans Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 3/4(1996-12-01), 297-300 0929-5305 3:4<297 1996 3 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer